17.25

1.32% -0.23

After Hours: 17.25

PepGen Inc (PEPG)

Overview News Price History Financials Discussions Forecast

PepGen Inc stock is currently priced at $17.25, with a 24-hour trading volume of 47,301. It has seen a -1.32% decreased in the last 24 hours and a +23.30% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $17.56 pivot point. If it approaches the $17.15 support level, significant changes may occur.

Previous Close:

$17.48

Open:

$17.38

24h Volume:

47,301

Market Cap:

$559.20M

Revenue:

Net Income/Loss:

$-78.63M

P/E Ratio:

-5.8876

EPS:

-2.9299

Net Cash Flow:

$-71.60M

1W Performance:

+4.10%

1M Performance:

+23.30%

6M Performance:

+143.30%

1Y Performance:

+41.39%

1D Range:

$16.94

$17.50

52W Range:

$3.72

$18.38

PepGen Inc Stock (PEPG) Company Profile

Name

PepGen Inc

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

781-797-0979

Address

245 Main Street, 2nd Floor, Cambridge

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PEPG's Discussions on Twitter

PepGen Inc Stock (PEPG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	H.C. Wainwright	Buy

PepGen Inc Stock (PEPG) Latest News

PepGen Inc Stock (PEPG) Financials Data

PepGen Inc (PEPG) Net Income 2024

PEPG net income (TTM) was -$78.63 million for the quarter ending December 31, 2023, a -13.78% decrease year-over-year.

PepGen Inc (PEPG) Cash Flow 2024

PEPG recorded a free cash flow (TTM) of -$71.60 million for the quarter ending December 31, 2023, a -13.61% decrease year-over-year.

PepGen Inc (PEPG) Earnings per Share 2024

PEPG earnings per share (TTM) was -$3.30 for the quarter ending December 31, 2023, a +6.70% growth year-over-year.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.